SUPPLEMENT
Q1 2026 — Financial disclosures
Q1 2026PDF · 9 pages1.1 MB
Merck & Co., Inc., Rahway, N.J., USA Financial Highlights Package First Quarter 2026 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q26....................................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q25....................................4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / International 1Q26.................................................6 Table 3b: Sales – Pharmaceutical Geographic Split....................................7 Table 4: Other (Income) Expense .............................................................8 -- 1 of 9 -- Sales 16,286 $ 15,529 $ 5% Costs, Expenses and Other Cost of sales 4,195 3,419 23% Selling, general and administrative 2,700 2,552 6% Research and development 12,592 3,621 * Restructuring costs 195 69 * Other (income) expense, net 138 (35) * (Loss) Income Before Taxes (3,534) 5,903 * Income Tax Provision 709 818 Net (Loss) Income (4,243) 5,085 * Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 6 Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA (4,240) $ 5,079 $ * (Loss) Earnings per Common Share Assuming Dilution (1) (1.72) $ 2.01 $ * Average Shares Outstanding Assuming Dilution (1) 2,472 2,531 Tax Rate -20.1% 13.9% * 100% or greater (1) Because the Company recorded a net loss in the first quarter of 2026, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change 1Q26 1Q25 1 -- 2 of 9 -- Sales 16,286 $ 15,529 $ 15,806 $ 17,276 $ 16,400 $ 65,011 $ 5% Costs, Expenses and Other Cost of sales 4,195 3,419 3,557 3,855 5,551 16,382 23% Selling, general and administrative 2,700 2,552 2,649 2,633 2,898 10,733 6% Research and development 12,592 3,621 4,048 4,234 3,886 15,789 * Restructuring costs 195 69 560 47 213 889 * Other (income) expense, net 138 (35) (7) (238) 432 151 * (Loss) Income Before Taxes (3,534) 5,903 4,999 6,745 3,420 21,067 * Income Tax Provision 709 818 571 958 458 2,804 Net (Loss) Income (4,243) 5,085 4,428 5,787 2,962 18,263 * Less: Net (Loss) Income Attributable to Noncontrolling Interests (3) 6 1 2 (1) 9 Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA (4,240) $ 5,079 $ 4,427 $ 5,785 $ 2,963 $ 18,254 $ * (Loss) Earnings per Common Share Assuming Dilution (1) (1.72) $ 2.01 $ 1.76 $ 2.32 $ 1.19 $ 7.28 $ * Average Shares Outstanding Assuming Dilution (1) 2,472 2,531 2,513 2,498 2,488 2,507 Tax Rate -20.1% 13.9% 11.4% 14.2% 13.4% 13.3% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a % Change 4Q 1Q Full Year 2026 1Q 1Q 2Q 3Q 2025 2 -- 3 of 9 -- First Quarter Cost of sales 4,195 $ 1,014 237 1,251 2,944 $ Selling, general and administrative 2,700 32 32 2,668 Research and development 12,592 34 34 12,558 Restructuring costs 195 195 195 – Other (income) expense, net 138 (180) (180) 318 Loss Before Taxes (3,534) (1,046) (466) 180 (1,332) (2,202) Income Tax Provision (Benefit) 709 (202) (3) (85) (3) 39 (3) (248) 957 Net Loss (4,243) (844) (381) 141 (1,084) (3,159) Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA (4,240) (844) (381) 141 (1,084) (3,156) Loss per Common Share Assuming Dilution (4) (1.72) $ (0.34) (0.16) 0.06 (0.44) (1.28) $ Tax Rate -20.1% -43.5% Only the line items that are affected by non-GAAP adjustments are shown. GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP MERCK & CO., INC., RAHWAY, N.J., USA FIRST QUARTER 2026 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a (4) Because the Company recorded a net loss in the first quarter of 2026, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the 2025 Verona Pharma plc acquisition. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs, associated with activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. 3 -- 4 of 9 -- First Quarter Cost of sales 3,419 $ 620 36 656 2,763 $ Selling, general and administrative 2,552 23 23 2,529 Research and development 3,621 7 7 3,614 Restructuring costs 69 69 69 – Other (income) expense, net (35) (3) (107) (110) 75 Income Before Taxes 5,903 (647) (105) 107 (645) 6,548 Income Tax Provision (Benefit) 818 (117) (3) (18) (3) 22 (3) (113) 931 Net Income 5,085 (530) (87) 85 (532) 5,617 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,079 (530) (87) 85 (532) 5,611 Earnings per Common Share Assuming Dilution 2.01 $ (0.21) (0.03) 0.03 (0.21) 2.22 $ Tax Rate 13.9% 14.2% Only the line items that are affected by non-GAAP adjustments are shown. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. MERCK & CO., INC., RAHWAY, N.J., USA FIRST QUARTER 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2b Adjustment Subtotal Non-GAAP 4 -- 5 of 9 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2026 2025 1Q 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $16,286 $15,529 $15,806 $17,276 $16,400 $65,011 5 3 PHARMACEUTICAL 14,349 13,638 14,050 15,611 14,843 58,142 5 2 Oncology Keytruda 7,906 7,205 7,956 8,142 8,337 31,641 10 6 Keytruda Qlex 128 5 35 40 - - Alliance Revenue – Lynparza (2) 341 312 370 379 389 1,450 9 6 Alliance Revenue – Lenvima (2) 256 258 265 258 272 1,053 -1 -2 Welireg 199 137 162 196 220 716 45 43 Alliance Revenue – Reblozyl (3) 148 119 107 136 164 525 25 25 Vaccines (4) Gardasil/Gardasil 9 1,069 1,327 1,126 1,749 1,031 5,233 -19 -22 ProQuad/M-M-R II/Varivax 538 539 609 684 619 2,451 - -2 RotaTeq 206 228 121 204 119 673 -10 -11 Vaxneuvance 202 230 229 226 140 825 -12 -16 Capvaxive 142 107 129 244 279 759 33 31 Enflonsia 1 79 21 100 - - Cardiometabolic & Respiratory Winrevair 525 280 336 360 467 1,443 88 87 Ohtuvayre 131 178 178 - - Alliance Revenue - Adempas/Verquvo (5) 109 106 123 112 129 470 3 3 Adempas (6) 78 68 80 82 83 312 15 5 Infectious Diseases Bridion 472 441 461 439 499 1,841 7 7 Prevymis 272 208 228 266 275 978 31 26 Zerbaxa 82 70 74 81 87 312 17 14 Delstrigo 75 67 83 77 79 306 12 1 Isentress/Isentress HD 59 90 86 82 67 325 -34 -36 Dificid 34 83 96 43 25 247 -59 -59 Lagevrio 28 102 83 138 57 380 -73 -73 Diabetes Januvia 367 549 372 382 302 1,604 -33 -33 Janumet 207 247 251 243 199 940 -16 -18 Other Pharmaceutical (7) 774 865 703 1,004 770 3,340 -11 -12 ANIMAL HEALTH 1,791 1,588 1,646 1,615 1,505 6,354 13 6 Livestock 1,064 924 961 1,023 987 3,896 15 8 Companion Animal 727 664 685 592 518 2,458 9 4 Other Revenues (8) 146 303 110 50 52 515 -52 4 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $44 million in the first quarter of 2026 and 2025, respectively. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $95 million in the first quarter of 2026 and 2025, respectively. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,314 million and $2,607 million in the first quarter of 2026 and 2025, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the Company's marketing territories. 5 -- 6 of 9 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2026 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 1Q 2026 1Q 2025 % Change 1Q 2026 1Q 2025 % Change 1Q 2026 1Q 2025 % Change TOTAL SALES (1) $16,286 $15,529 5 $9,164 $8,522 8 $7,122 $7,007 2 PHARMACEUTICAL 14,349 13,638 5 8,512 7,927 7 5,837 5,711 2 Oncology Keytruda 7,906 7,205 10 4,599 4,308 7 3,307 2,897 14 Keytruda Qlex 128 - 106 - 21 - Alliance Revenue – Lynparza (2) 341 312 9 149 145 3 192 168 15 Alliance Revenue – Lenvima (2) 256 258 -1 176 186 -5 80 72 11 Welireg 199 137 45 152 123 24 47 15 * Alliance Revenue – Reblozyl (3) 148 119 25 128 101 27 20 18 11 Vaccines (4) Gardasil/Gardasil 9 1,069 1,327 -19 485 536 -10 585 790 -26 ProQuad/M-M-R II/Varivax 538 539 0 409 423 -3 129 116 11 RotaTeq 206 228 -10 165 164 0 42 64 -35 Vaxneuvance 202 230 -12 123 139 -11 78 92 -15 Capvaxive 142 107 33 118 106 11 23 1 * Enflonsia 1 - -1 - 3 - Cardiometabolic & Respiratory Winrevair 525 280 88 477 268 78 48 12 * Ohtuvayre 131 - 131 - Alliance Revenue - Adempas/Verquvo (5) 109 106 3 109 97 12 9 -100 Adempas (6) 78 68 15 78 68 15 Infectious Diseases Bridion 472 441 7 427 378 13 45 63 -29 Prevymis 272 208 31 135 102 32 138 106 30 Zerbaxa 82 70 17 52 42 22 30 28 9 Delstrigo 75 67 12 10 15 -34 65 52 26 Isentress/Isentress HD 59 90 -34 35 51 -31 24 39 -38 Dificid 34 83 -59 24 72 -67 10 11 -10 Lagevrio 28 102 -73 16 35 -54 12 67 -83 Diabetes Januvia 367 549 -33 252 344 -27 116 204 -43 Janumet 207 247 -16 68 65 5 139 182 -23 Other Pharmaceutical (7) 774 865 -11 167 227 -26 605 637 -5 ANIMAL HEALTH 1,791 1,588 13 519 502 3 1,272 1,086 17 Livestock 1,064 924 15 211 194 9 853 730 17 Companion Animal 727 664 9 308 308 0 419 356 18 Other Revenues (8) 146 303 -52 133 93 43 13 210 -94 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $44 million on a global basis in the first quarter of 2026 and 2025, respectively. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $95 million in the first quarter of 2026 and 2025, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,314 million and $2,607 million on a global basis in the first quarter of 2026 and 2025, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- MERCK & CO., INC., RAHWAY, N.J., USA PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 2026 2025 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q TOTAL PHARMACEUTICAL $14,349 $13,638 $14,050 $15,611 $14,843 $58,142 5 United States 8,512 7,927 8,328 9,493 8,662 34,409 7 % Pharmaceutical Sales 59.3% 58.1% 59.3% 60.8% 58.4% 59.2% Europe (1) 2,725 2,384 2,551 2,675 2,839 10,449 14 % Pharmaceutical Sales 19.0% 17.5% 18.2% 17.1% 19.1% 18.0% Latin America 624 589 654 691 644 2,578 6 % Pharmaceutical Sales 4.3% 4.3% 4.7% 4.4% 4.3% 4.4% Asia Pacific (other than China and Japan) 569 535 609 593 586 2,323 6 % Pharmaceutical Sales 4.0% 3.9% 4.3% 3.8% 4.0% 4.0% Japan 535 651 604 693 684 2,632 -18 % Pharmaceutical Sales 3.7% 4.8% 4.3% 4.4% 4.6% 4.5% Eastern Europe/Middle East/Africa 413 435 451 365 348 1,598 -5 % Pharmaceutical Sales 2.9% 3.2% 3.2% 2.3% 2.3% 2.7% China (2) 353 668 407 377 364 1,816 -47 % Pharmaceutical Sales 2.5% 4.9% 2.9% 2.4% 2.5% 3.1% Canada 137 125 135 134 153 547 9 % Pharmaceutical Sales 1.0% 0.9% 1.0% 0.9% 1.0% 0.9% Other 481 324 311 590 563 1,790 48 % Pharmaceutical Sales 3.3% 2.4% 2.1% 3.9% 3.8% 3.2% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. (2) Gardasil/Gardasil 9 sales in China were $0 million and $193 million in the first quarter of 2026 and 2025, respectively. 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q26 1Q25 Interest income (35) $ (109) $ Interest expense 479 313 Exchange losses 38 90 Income from investments in equity securities, net (1) (168) (90) Net periodic defined benefit plan (credit) cost other than service cost (134) (148) Other, net (42) (91) Total 138 $ (35) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC., RAHWAY, N.J., USA OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --